Company news

Find out what’s going on within Adelphi Values, from new interesting people making a difference to updates on our latest work.

Increasing numbers of rare diseases are being recognised and more medicines to treat them are being developed. There are several unique challenges for developing evidence packages in rare diseases such as the paucity of information on patient populations, disease progression and appropriate Clinical Outcome Assessments (COAs). As with all clinical… Read More

Oncology is an area that is notoriously hard to achieve patient-reported outcome label claims, but experts at Adelphi Values continue to evaluate ways to work with the FDA guidelines to ensure data are robust and stand up to the scrutiny of regulators. To demonstrate this, and in collaboration with Novartis,… Read More

We are exhibiting and presenting at the 18th Annual European Conference of ISPOR, the International Society for Pharmacoeconomics and Outcomes Research, which takes place from 9th-11th November 2015 in Milan, Italy. Representatives from each of our four practices and both the UK and US offices, will be attending the event. Read More

Adelphi will be at ISPOR US in May, exhibiting at booths 411/413.  Senior representatives from Adelphi Values will be there alongside colleagues from our sister company Adelphi Real World. The theme for the conference this year is titled ‘Integrating Big Data, Patient Data, and Cost-Effectiveness into Clinical Practice: Promise and… Read More

Announcing a newly created global leadership team and growth in our senior management team with three new recruits in recent weeks. Established in 1993, Adelphi Values has been a global leader in patient-centered and healthcare value research for over 20 years. Throughout this time, we have expanded our offering to… Read More

Cheryl Coon, Associate Director from our Endpoint Development & Outcomes Assessment practice will be presenting at the DIA 2014 50th Annual Meeting in San Diego on June 19th. The session titled ‘Moving Beyond the Traditional Psychometric Validation of New Phase 3 Clinical Outcome Assessments’ will be on June 19, 9:00AM… Read More

We are delighted to report that on February 18 2014, Chelsea Therapeutics announced that the US Food and Drug Administration (FDA) granted accelerated approval of NortheraTM (Droxidopa) for the treatment of symptomatic neurogenic hypotension (NOH).  Not only is this the first new treatment for NOH in nearly… Read More

On July 29th Adelphi Values will move to Atlantic Wharf – a building recognized last year as Boston’s first ‘green’ skyscraper.  The 1.2 million square-foot mixed-use project made the headlines in 2012 when Boston Properties received the Global Award for Excellence from the Urban Land Institute for the restored historic… Read More